Granted Patent B2

US 12,409,457 · App. 17/021,100 · Granted Sep 9, 2025

Inventors: Lotien Richard Huang (Chestnut Hill, MA); Thomas A. Barber (Sudbury, MA); Bruce L. Carvalho (Watertown, MA); Ravi Kapur (Sharon, MA); Paul Vernucci (Billerica, MA); Mehmet Toner (Charlestown, MA); Zihua Wang (Newton, MA)

Assignees: The General Hospital Corporation; GPB Scientific, LLC

B03C1/30B01L3/502746B01L3/502753B01L3/502761B03C1/32C12M47/04C12M47/06C12Q1/686G01N1/4077G01N33/5044B01L2200/0647B01L2300/0816B01L2300/0864B01L2400/0406B01L2400/0409B01L2400/0415B01L2400/043B01L2400/0472B01L2400/0487B01L2400/086B03C2201/18B33Y80/00G01N1/40G01N2035/00237Y10T137/0318Y10T137/8593Y10T436/25Y10T436/25375

Abstract

Claims (32)

1. A method of enriching a sample in fetal cells relative to maternal cells, the method comprising:

enriching a mixture of maternal and fetal cells for fetal cells relative to maternal cells to produce an enriched sample;

performing lysis of all types of cells in the enriched sample to lyse both maternal cells and fetal cells in the enriched sample to release maternal nuclei and fetal nuclei;

depositing the maternal nuclei and fetal nuclei onto a solid support;

identifying the fetal nuclei; and

performing genetic analysis of fetal DNA from the fetal nuclei.

2. The method of claim 1 , wherein the enriching comprises introducing the mixture of maternal and fetal cells into a device capable of enriching fetal cells relative to maternal cells based on size, shape, deformability, or affinity.

3. The method of claim 1 , wherein the sample is selected from blood, lymph, cerebrospinal fluid, urine, and cervical lavage.

4. The method of claim 1 , wherein the genetic analysis comprises sequencing of the fetal DNA.

5. The method of claim 1 , wherein the genetic analysis comprises polymerase chain reaction (PCR) or whole genome amplification (WGA).

6. The method of claim 1 , wherein the genetic analysis comprises analysis of short tandem repeats (STR).

7. The method of claim 1 , wherein the genetic analysis comprises analysis of single nucleotide point mutations (SNP), deletions, or translocations.

8. The method of claim 1 , wherein the genetic analysis comprises detecting chromosomal aneuploidies.

9. The method of claim 8 , wherein the chromosomal aneuploidies are detected using comparative genome hybridization.

10. The method of claim 1 , wherein the genetic analysis comprises determining the presence or absence of a genetic abnormality.

11. The method of claim 10 , wherein the genetic abnormality is a chromosomal, DNA, or RNA abnormality.

12. The method of claim 11 , wherein the chromosomal abnormality comprises an autosomal chromosome abnormality or a sex chromosome abnormality.

13. The method of claim 12 , wherein the chromosomal abnormality comprises an autosomal chromosome comprising Angleman syndrome (15qll.2-q 13), cri-du-chat syndrome (5p-), Di George syndrome and Velo-cardiofacial syndrome (22ql 1.2), Miller-Dieker syndrome (17p13.3), Prader-Willi syndrome (15qll.2-q13), retinoblastoma (31q14), Smith-Magenis syndrome (17pl 1.2), trisomy 13, trisomy 16, trisomy 18, trisomy 21 (Down syndrome), triploidy, Williams syndrome (7 q 11.23), or Wolf-Hirschhorn (4p-).

14. The method of claim 12 , wherein the chromosomal abnormality comprises a sex chromosome abnormality comprising Kallman syndrome (Xp22.3), steroid sulfate deficiency (STS) (Xp22.3), X-linked ichthiosis (Xp22.3), Klinefelter syndrome (XXY); fragile X syndrome; Turner syndrome; metafemales or trisomy X; or monosomy X.

15. The method of claim 1 , wherein the solid support is a glass slide.

16. The method of claim 1 , wherein the lysing comprises contacting cells with a protease.

17. The method of claim 1 , wherein the lysing comprises contacting cells with a hypotonic solution.

18. The method of claim 1 , wherein the lysing comprises contacting cells with a lysis buffer.

19. The method of claim 1 , further comprising contacting nuclei with an endonuclease.

20. The method of claim 1 , further comprising contacting nuclei with an exonuclease.

21. The method of claim 1 , wherein extracted fetal DNA is bound to an array or other surface.

22. The method of claim 1 , wherein the enriching comprises introducing the mixture of maternal and fetal cells into a microfluidic device comprising a channel having a structure that deterministically directs fetal nucleated cells in a first direction and at least some maternal cells in a second direction based on deterministic lateral displacement.

23. The method of claim 22 , wherein the microfluidic device is a duplex device comprising a channel comprising a first section comprising first and second outer regions, each outer region comprising a structure that deterministically directs particles having a hydrodynamic size above a critical size in a first direction and particles having a hydrodynamic size below the critical size in a second direction, wherein the first and second outer regions are aligned in parallel in the channel.

24. The method of claim 1 , wherein the genetic analysis comprises hybridizing fetal nucleic acids to oligonucleotides in solution, attached to beads, or bound to an array or other surface to identify unique molecular markers.

25. The method of claim 1 , wherein the lysing comprises contacting the cells with a chaotropic salt solution or a detergent solution.

26. The method of claim 1 , wherein the lysing comprises contacting the cells with an acid alcohol solution.

27. The method of claim 1 , wherein the lysing results in lysis of >99% of enucleated cells and >99% of nucleated cells.

Assignments (8)

Continuity (8)

References Cited (400)